16 | Cancer Commissioning Strategy Framework Cancer Commissioning Strategy Framework | 17 1. CANCER COMMISSIONING STRATEGY INITIATIVES North Central London Cancer Commissioning Strategy 2025-2026 Implementation Plan Appendix 1 - North Central London Cancer Commissioning Strategy 2025-2026 Implementation Plan Appendix 1 - High-Level North Central London Cancer Commissioning Strategy 2025-2026 Implementation Plan MILESTONES CANCER ALLIANCE STRATEGIC AIM ALIGNMENT A. Fragile Service Review B. Specialised Commissioning Delegation C. Cancer Commissioning Strategy 1. ERG’s to complete the “Tumour Specific Cancer Fragility Checklist” baseline assessment. To include Specialised Commissioning. delegated elements of cancer services such as specialist surgery. Q1 25/26 2. Gather data to support a strategic review of fragile cancer services, as identified following the baseline assessment. Q2 25/26 3. Launch a “call to action” exercise with partners to identify levels of appetite to support critical areas. Q2 25/26 4. Undertake stakeholder engagement, to identify key goals and priorities for cancer services transformation requirements. Q2 25/26 5. Update the national and regional cancer landscape analysis to incorporate key deliverables from ten-year plan (published Spring 2025) and cancer plan (published Summer 2025) Q3 25/26 6. Develop a 5-year cancer commissioning strategy for NCL, aligned to clinical priorities identified via the fragile services review. Q3 25/26 SA1, SA2, SA3, SA4, SA5, SA6 2. EARLIER DIAGNOSIS INITIATIVES MILESTONES CANCER ALLIANCE STRATEGIC AIM ALIGNMENT A. Surveillance Service Model Development 1. Development of a tariff or alternative funding mechanism, to support the substantive commissioning of surveillance services across NCL. Q1 25/26 2. Identify a list of potential surveillance services for NCL. Undertake analysis to ascertain impact for each of these, specifically potential for avoiding cancer/earlier diagnosis, and work with ICB to agree commissioning approach for each of these. Q3-4 25/26 3. Roll out surveillance services comms and education programme across NCL. Q3-4 25/26 SA1, SA4 B. Lynch Syndrome (LS) Surveillance 1. Finalise modelling and business case and take through ICB governance process to ensure sustainability of the LS hub service in NCL. Q1 -2 25/26 2. Sustainably commissioned service in place. Q4 25/26 3. Service monitoring and evaluation. Q4 25/26 C. Ovarian Surveillance Hub for Ovarian Cancer 1. Launch ROCA testing pathway (non-recurrent cancer transformation funding) for patients on a waiting list for risk reducing surgery. Q1 25/26 2. Finalise modelling and business case and take through ICB governance process to ensure sustainability of the ROCA surveillance service in NCL. Q1 -2 25/26 3. Sustainably commissioned service in place. Q4 25/26 4. Service monitoring and evaluation. Q4 25/26
RkJQdWJsaXNoZXIy NTI5NzM=